A Phase 3 Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy

Mark Martens, MD

Xuezhi Jiang, MD
Michelle Williams-Robinson, MD

To assess the safety and efficacy of respiratory syncytial virus (RSV) stabilized prefusion F subunit vaccine (RSVpreF) in pregnant women and infants.

Healthy women ≥18 and ≤49 years of age who are between 24 and 36 weeks of gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy

Had an ultrasound examination performed at ≥18 weeks of pregnancy with no significant fetal abnormalities observed

Documented negative HIV antibody test, syphilis test, and hepatitis B virus (HBV) surface antigen test during this pregnancy

Pre-pregnancy body mass index (BMI) of >40 kg/m²
Current pregnancy resulting from in vitro fertilization
Current pregnancy complications or abnormalities at the time of consent such as: pre-eclampsia, eclampsia, uncontrolled gestational hypertension, placental abnormality, significant bleeding or blood clotting disorder, endocrine disorders
Prior pregnancy complications or abnormalities at the time of consent such as prior pre-term delivery ≤34 weeks’ gestation, prior stillbirth or neonatal death, previous infant with a known genetic disorder or significant congenital anomaly
Current alcohol abuse or illicit drug use
Affiliations & Sponsors  
Pfizer

Status  
Open to Enrollment

Keywords  
Respiratory Syncytial Virus, RSV, vaccine, pregnancy, maternal immunization